Cardiac effects of SGLT2 inhibitors: The sodium hypothesis

Cardiovascular Research

Volumn 114, Issue 1, 2018, Pages 12-18

  Bertero, Edoardo ^a,b   Prates Roma, Leticia ^a   Ameri, Pietro ^b   Maack, Christoph ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Diabetes; EMPA REG OUTCOME; Empagliflozin; Heart failure; Mitochondria; Sodium

Indexed keywords

DIURETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BIOLOGICAL MARKER; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIAC MUSCLE CELL; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENERGY RESOURCE; HEART FAILURE; HEART FUNCTION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; SODIUM CELL LEVEL; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DIURESIS; DRUG EFFECT; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIURESIS; ENERGY METABOLISM; HOSPITALIZATION; HUMANS; MYOCYTES, CARDIAC; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85040582993     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx149     Document Type: Review

References (77)

1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004;27:1879-1884.
2. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-113.
3. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr, Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703.
4. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diabetes Vasc Dis Res 2013;10:330-336.
5. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. and the Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52: 2288-2298.
6. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucoselowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015;3:356-366.
7. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes and cardiovascular events. Diabetes Care 2010;33:1389-1394.
8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. S Inzucchi SE for the EMPA-REG OUTCOME Investigators. EMPA, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
9. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi S. on behalf of the EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016;37:1526-1534.
10. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017. doi: 10.1056/NEJMoa1611925.
11. McMurray J. EMPA-REG: The "diuretic hypothesis." J Diabetes Complications 2016;30: 3-4.
12. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-1114.
13. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 2016;39:1115-1122.
14. Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radovi-c N, Jadrijevi-c S, Aleksic I, Walles T, Sauvant C, Saboli-c I, Koepsell H. Localizations of Na(\+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 2015;467: 1881-1898.
15. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92.
16. Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol 2017;243:86-90.
17. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-517.
18. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-794.
19. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-3434.
20. Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 2017. doi: 10.1111/dom.12970.
21. Norton L, Shannon C, Fourcaudot M, Hu C, Wang N, Ren W, Song J, Abdul-Ghani M, DeFronzo RA, Ren J, Jia W. Sodium-glucose (SGLT) and glucose (GLUT) transporter expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 2017. doi: 10.1111/dom.13003.
22. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:e001007.
23. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-3176.
24. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle H, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.
25. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.
26. Tang H, Xi Zhang X, Zhang J, Li Y, Del Gobbo LC, Zhai S, Yiqing Song Y. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: A meta-analysis of randomised controlled trials. Diabetologia 2016;59:2546-2551.
27. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mö rschel L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:1087-1095.
28. Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther 2014;36: 698-710.
29. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucoseregulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15:853-862.
30. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
31. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213:263-276.
32. Labbé SM, Grenier-Larouche T, Noll C, Phoenix S, Guérin B, Turcotte EE, Carpentier AC. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012;61:2701-2710.
33. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
34. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004; 95: 568-578.
35. Bayeva M, Sawicki KT, Ardehali H. Taking diabetes to heart: Deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Coll Cardiol 2013;2:e000433.
36. Wende AR, Abel DE. Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801: 311-319.
37. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339:211-214.
38. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol 2013;304:1060-1076.
39. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity 2012;20:1645-1652.
40. Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, Nagata T, Fukuzawa T, Yamane M, Honda K, Suzuki Y, Kawabe Y. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014;4:e125.
41. Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74.
42. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: A 24-week, randomized, double-blind, placebocontrolled, phase III study. Expert Opin Pharmacother 2014;15:1501-1515.
43. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E. Shift to fatty substrates utilization in response to sodium-glucose cotransporter-2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016;65:1190-1195.
44. Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J 2011;38:533-538.
45. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The failing heart relies on ketone bodies as a fuel. Circulation 2016;133:698-705.
46. Lopaschuk GD, Verma S. Empagliflozin's fuel hypothesis: Not so soon. Cell Metab 2016;24:200-202.
47. Neubauer S. The failing heart: An engine out of fuel. N Engl J Med 2007;356: 1140-1151.
48. Lygate CA, Aksentijevic D, Dawson D, Ten Hove M, Phillips D, de Bono JP, Medway DJ, Sebag-Montefiore LM, Hunyor I, Channon K, Clarke K, Zervou S, Watkins H, Balaban R, Neubauer S. Living without creatine: Unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ Res 2013; 112:945-955.
49. Nickel AG, Lö ffler J, Maack C. Myocardial energetics in heart failure. Basic Res Cardiol 2013;108:358.
50. Clancy CE, Chen-Izu Y, Bers DM, Belardinelli L, Boyden PA, Csernoch L, Despa S, Fermini B, Hool LC, Izu L, Kass RS, Lederer WJ, Louch WE, Maack C, Matiazzi A, Qu Z, Rajamani S, Rippinger CM, Sejersted OM, O'rourke B, Weiss JN, Varró A, Zaza A. Deranged sodium to sudden death. J Physiol (Lond) 2015;593:1331-1345.
51. Bay J, Kohlhaas M, Maack C. Intracellular Na\+ and cardiac metabolism. J Mol Cell Cardiol 2013;61:20-27.
52. Maack C, O'rourke B. Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol 2007;102:369-392.
53. Kohlhaas M, Liu T, Knopp A, Zeller T, Ong MF, Böhm M, O'rourke B, Maack C. Elevated cytosolic Na\+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 2010;121:1606-1613.
54. Weber CR, Piacentino IIIV, Houser SR, Bers DM. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation 2003;108:2224-2229.
55. O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure. I: Experimental studies. Circ Res 1999;84:562-570.
56. Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM. Intracellular Na concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002;105:2543-2548.
57. Hobai IA, Maack C, O'rourke B. Partial inhibition of sodium/calcium exchange restores cellular calcium handling in canine heart failure. Circ Res 2004;95:292-299.
58. Studer R, Reinecke H, Bilger J, Eschenhagen T, Böhm M, Hasenfuss G, Just H, Holtz J, Drexler H. Gene expression of the cardiac Na(\+)-Ca2\+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-453.
59. Hobai IA, O'rourke B. Enhanced Ca(2\+)-activated Na(\+)-Ca2\+ exchange activity in canine pacing-induced heart failure. Circ Res 2000;87:690-698.
60. Kohlhaas M, Maack C. Adverse bioenergetic consequences of Na(\+)-Ca2\+ exchanger-mediated Ca2\+ influx in cardiac myocytes. Circulation 2010;122:2273-2280.
61. Baartscheer A, Schumacher CA, Belterman CN, Coronel R, Fiolet JW. [Na\+]i and the driving force of the Na\+/Ca2\+-exchanger in heart failure. Cardiovasc Res 2003; 57:986-995.
62. Swift F, Birkeland JA, Tovsrud N, Enger UH, Aronsen JM, Louch WE, Sjaastad I, Sejersted OM. Altered Na\+/Ca(2\+)-exchanger activity due to downregulation of Na\+/K(\+)-ATPase alpha2-isoform in heart failure. Cardiovasc Res 2008;78:71-78.
63. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 2009;84:111-118.
64. Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na\+ concentration is elevated in diabetic hearts due to enhanced Na\+-glucose cotransport. J Am Heart Assoc 2015;4:002183.
65. Wagner S, Rokita AG, Anderson ME, Maier LS. Redox regulation of sodium and calcium handling. Antioxid Redox Signal 2013;18:1063-1077.
66. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007;93:903-907.
67. Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, Sidor A, Abraham TP, O'rourke B. Inhibiting mitochondrial Na\+/Ca2\+ exchange prevents sudden death in a guinea pig model of heart failure. Circ Res 2014;115:44-54.
68. Sabolic I, Vrhovac I, Eror DB, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, Sauvant C, Kipp H, Vallon V, Koepsell H. Expression of Na\+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 2012;302:C1174-C1188.
69. Zhou L, Cryan EV, D'andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na\+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003;90:339-346.
70. Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na\+ through inhibition of the cardiac Na\+/H\+ exchanger in rats and rabbits. Diabetologia 2017;60:568-573.
71. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 2017;16:9.
72. Voelkl J, Lin Y, Alesutan I, Ahmed MSE, Pasham V, Mia S, Gu S, Feger M, Saxena A, Metzler B, Kuhl D, Pichler BJ, Lang F. Sgk1 sensitivity of Na\+/H\+ exchanger activity and cardiac remodeling following pressure overload. Basic Res Cardiol 2012;107:236.
73. Schmieder R, Ott C, Linz P, Jumar A, Friedrich S, Titze J, Hammon M, Uder M, Kistner I. SGLT2 inhibition with dapagliflozin reduces tissue sodium content. J Hypertens 2016;34(Suppl 1):e76.
74. Schneider MP, Raff U, Kopp C, Scheppach JB, Toncar S, Wanner C, Schlieper G, Saritas T, Floege J, Schmid M, Birukov A, Dahlmann A, Linz P, Janka R, Uder M, Schmieder RE, Titze JM, Eckardt KU. Skin sodium concentration correlates with left ventricular hypertrophy in CKD. J Am Soc Nephrol 2017;28:1867-1876.
75. Takewaki S, Kuro O. M, Hiroi Y, Yamazaki T, Noguchi T, Miyagishi A, Nakahara KI, Aikawa M, Manabe I, Kazaki Y, Nagai R. Activation of Na(\+)-H\+ antiporter (NHE-1) gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J Mol Cell Cardiol 1995;27:729-742.
76. Anzawa R, Bernard M, Tamareille S, Baetz D, Confort-Gouny S, Gascard JP, Cozzone P, Feuvray D. Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice. Diabetologia 2006;49:598-606.
77. Darmellah A, Baetz D, Prunier F, Tamareille S, Rücker-Martin C, Feuvray D. Enhanced activity of the myocardial Na\+/H\+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: Critical role of Akt. Diabetologia 2007;50:1335-1344.